期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 839, 期 -, 页码 57-65出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2018.09.023
关键词
Cholangiocarcinoma; Indirubin-3&PRIME-oxime; Cell-Cycle; Apoptosis
资金
- Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi City, Taiwan [R105-01]
Cholangiocarcinoma (CCA) is one of the most serious of all cancers and a major public health problem. CCA is an extremely invasive cancer, and the survival rate for CCA patients is only 24 months after diagnosis. Although surgery and chemotherapy can extend the survival rate to 5 years, < 20-40% of CCA patients will survive this long; therefore, it is crucial to discover an effective chemotherapeutic agent for CCA. Indirubin-3'-oxime (I30), a derivative of indirubin, has been shown to suppress cell proliferation and induce cell-cycle arrest and cell apoptosis in various human cancers. In this study, four human CCA cell lines-NOZ, HuCCT1, OCUG-1, and 0Z-were used to evaluate the anticancer properties of 130. Cell viability, cell-cycle arrest, and apoptosis were assessed using Western blotting, immunofluorescence, and flow cytometry analysis. The data show that 130 treatment can inhibit cell proliferation and induce cell-cycle arrest, and caspase-dependent apoptosis in CCA cells. These findings suggest that 130 could suppress tumor growth by regulating the cell cycle and inducing apoptosis, and is a potential therapeutic agent for treating human CCA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据